The 5D4 antibody (anti-cyclin D1/D2) related antigen: Cytoplasmic staining is correlated to the progression of gastric cancer |
| |
Authors: | Yohei Yasogawa Yasuo Takano Isao Okayasu Akira Kakita |
| |
Affiliation: | Department of Surgery, Kitazato Institute Medical Center Hospital;Departments of Pathology, University of Kitasato School of Medicine, Kanagawa, Japan;Departments of Surgery, University of Kitasato School of Medicine, Kanagawa, Japan |
| |
Abstract: | In order to clarify the relationship between cyclin D1 and 02 (CD1/CD2) overexpression and progression, 191 gastric cancer cases (81 early and 110 advanced cancers) were investigated using the 504 monoclonal antibody for both CD1/CD2 in immunohistochemistry. 5D4 immunoreactlvity was noted in 68 (35.6%) cases, staining being restricted to the nucleus In 27 (14.1%) cases, the cytoplasm in 34 (17.8%) cases, and its presence in both the nucleus and cytoplasm in seven (3.7%). Cases demonstrating cytoplasmic positiv-ity, including both positive cases, were significantly more frequent in advanced cancers (P = 0.010), those having lymph node metastasis ( P = 0.004) and cases showing cancer invasion of vessels (P = 0.00S), although no relatlon to histological malignant grading was apparent. In contrast, cases of nuclear positivity behaved no differently from 5D4-negative cases. Statistics showed a trend where survival in patients was worse in the cytoplasm-positive cases than the cytoplasm-negative group. However, multivariate analysis revealed no Independent statlstical significance in the cytoplasmic positivity of prognosis. Additional studies using DCS-6 antlbody for CD1 and 617 antibody for CD2, suggest that nuclear staining of 5D4 indicates the presence of CD1 but cytoplasmic staining is derived from an antigen that is related to CD2. In conclusion, the present results indicate that the accumulation of CD2 in the cytoplasm may play some role In the progression of gastric cancers but not prognosis; however, CD1 overexpression is not linked to either. |
| |
Keywords: | cyclin D1/D2 gastric cancer prognosis progression |
|
|